New drug BR108 tested in blood cancer patients – early results uncertain
NCT ID NCT06018506
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested an experimental drug called BR108 in 8 adults with advanced blood cancers (lymphoma, leukemia, or myelodysplastic syndrome) that had not responded to prior treatments. The drug was given by IV infusion twice per cycle. The main goals were to check safety and see if the drug shrinks tumors. The trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BR108 injection (a drug given into the vein)
- What this could lead to
- If it works, this could point toward a new treatment option for certain blood cancers that have not responded to other therapies.
- What could go wrong
- This is a very early, small Phase 1 trial (only 8 participants) that was terminated early. It is designed mainly to check safety, not effectiveness, and many early-stage drugs never advance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Can a menin-blocking drug outsmart stubborn leukemia?